Kornimate/medical-research-clean huggingface dataset:
preparation regimens to improve capsule endoscopy visualization and diagnostic yield

Conditions: Obscure Gastrointestinal Bleeding

Summary: small bowel capsule endoscopy (sbce) has become an important tool in clinical practice since its introduction in 2000. this non-invasive method allows the visualization of small bowel mucosa, being essential in the management of many conditions, such as suspected small bowel bleeding, inflammatory bowel diseases and intestinal polyposis syndromes. despite recommendations concerning sbce in different pathologies, there are still some technical concerns to be addressed. the optimal preparation for sbce has been one of these controversial issues. currently, the european society of gastrointestinal endoscopy (esge) recommends that patients ingest a purgative agent (2l of polyethylene glycol, peg) and antifoaming agents for sbce, because it was associated with a better visualization. however, it remains unclear which is the optimal timing for purgative use. furthermore, the use of a booster agent after capsule ingestion is already performed in colon capsule endoscopy, but less is known about its application in sbce. also, it remains to be clarified whether a better visualization results in higher diagnostic yield and impacts patients' outcomes. therefore, the global aim of this prospective, randomized, multi-centric study is to determine the optimal timing and preparation for small-bowel capsule endoscopy (regardless of the equipment used), comparing four groups of different preparation protocols: * protocol 1) 1l of moviprep® solution the night before the procedure * protocol 2) 1l of moviprep® solution up to 2h before the procedure * protocol 3) 0.5l of moviprep® solution up to 2h before the procedure plus 0.5l of moviprep® solution after the capsule had reached the duodenum (assessed with real-time viewer) * protocol 4) 1l of moviprep® solution after the capsule had reached the duodenum (assessed using real-time viewer)


Eligibility criteria:
inclusion criteria: * be 18 years old or older * present ogib (either occult or overt) * agree with study's procedures and have signed the informed consent for the study and sbce, prior to sbce procedure exclusion criteria: * patients performing capsule endoscopy in urgent setting for overt obscure gi bleeding * inpatients or bedridden * history of surgery of the esophagus, stomach, small bowel, or colon * history of abdominal or pelvic radiation therapy * suspected or confirmed stenosis or occlusion * suspected or confirmed bowel perforation * severe comorbidities, as defined by grade 3 "severe decompensation" in the adult comorbidity evaluation-27 index (ace-27) * pregnant women * patients using narcotics or prokinetics in the week before the sbce

Keywords: small bowel capsule endoscopy obscure gastrointestinal bleeding bowel preparation
evaluating the safety and efficacy of autologous adipose tissue-derived mesenchymal stem cell transplantation on proinflammatory cytokines and anti-inflammatory cytokines on ageing-related low-grade inflammation patients.

Conditions: Aging Problems; Aging; Chronic Inflammation

Summary: single-group, open-label, phase i / ii clinical trial: evaluation of the safety of autologous adipose tissue-derived mesenchymal stem cell transplantation in inflammaging (ageing-related low-grade inflammation) patients.

the proposed study is a single-group, open-label, phase i / ii clinical trial in which the patients will be treated with two doses (100 million i.v) of autologous adipose tissue-derived mesenchymal stem cell transplantation. this study aims to evaluate the safety and efficiency of autologous adipose tissue-derived mesenchymal stem cell transplantation in inflammaging (ageing-related low-grade inflammation) patients. the inflammaging-patients are who have cytokine increasing (il6 and tnf alfa)

Eligibility criteria:
inclusion criteria: 1. male or female patient, age 40 to 64 years. 2. the inflammatory aging patient as defined in the protocol as tnf alpha or il6 at the time of screening was higher than the 95% healthy percentile value declared by the test system manufacturer. 3. have at least 2 of the 3 following diseases: * diabetes type ii * dyslipidemia * obesity \[the diagnosis and determination of accompanying diseases (diabetes, dyslipidemia, obesity) will be carried out according to the general guidance of the moh vietnam\]. 4. patients are using stable drugs for co-infection (diabetes mellitus, dyslipidemia, obesity) stably in the past 3 months. 5. agree to participate in research and agree to comply with the research examination and evaluation process. exclusion criteria: 1. patients with a blood-clotting disorder or hemophilia 2. patients with severe heart failure 3. acute respiratory pathology at the time of screening 4. patients with cancer or other acute illness need treatment. 5. patients with a history of allergy to anesthetics, anesthesia, and antibiotics 6. patients are planning to participate in another clinical trial while participating in the study 7. there are other conditions or circumstances in which it is difficult for researchers to ensure adherence to treatment in the judgment of researchers.

Keywords: ageing-related low-grade inflammation; inflammaging; aging
treatment of peri-implant mucositis by application of a spermidine-based gel

Conditions: Peri-implant Mucositis; Mucositis Oral

Summary: the aim of the study is to evaluate the potential of a spermidine-based topical gel as an adjuvant to non-surgical treatment of peri-implant mucositis. after a meticulous selection, patients will be randomly assigned to test (spermidine gel + non-surgical debridement) or control group (non-surgical debridement).

following the recording of the clinical parameters (bop, fmps, fmbs, pd), mechanical therapy (nsmd) will be performed in the test group (spermidine gel) by means of an ultrasonic scaler with a plastic tip. finally, the spermidine-based gel will be applied in the peri-implant sulcus using a blunt-tipped needle. control group will instead be treated only through the nsmd. finally, after 3 months the clinical parameters (bop, fmps, fmbs, pd) will be recorded again and the final evaluation will be performed. data analysis will be performed using statistical software.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * non-smokers and smokers ( ≤ 10 cigarettes/day); * presence of at least 1 implant in mucositis, clinically and radiographically detected; * the implant in mucositis (tissue-level or bone-level) must support a fixed prosthetic device (single crown), cemented or screwed. exclusion criteria: * cancer patients; * periodontally compromised patients; * uncontrolled diabetic patients; * prolonged antibiotic treatment or anti-inflammatory treatment in the previous 6 months; * pregnant or breastfeeding patients; * implants that support mobile prosthetic products; * implants in peri-implantitis, detected clinically and radiographically.

Keywords: peri-implant mucositis spermidine
predictors of pulmonary hypertension in patients with advanced lung diseases

Conditions: Pulmonary Hypertension

Summary: first, the aim of the study was to evaluate the usefulness of echocardiographic parameters for detecting pulmonary hypertension (ph) in patients with advanced lung disease referred for lung transplantation. second, to assess the prevalence of ph and to identify which hemodynamic, echocardiographic, pulmonary functional test, exercise capacity and biochemical parameters (especially nt-probnp) have an impact on survival in a cohort of patients with severe lung diseases referred for lung transplantation.


Eligibility criteria:
inclusion criteria: * advanced lung disease * qualification for lung transplantation * written informed consent * pulmonary capillary wedge pressure \< 15 mmhg exclusion criteria: * cancer, * history of idiopathic pulmonary hypertension, * primary valvular heart diseases, * coronary artery disease, * collagen vascular disease, * history or evidence of left ventricular dysfunction, * atrial fibrillation, * increased liver enzyme levels ( 3 times the upper laboratory limit), * renal dysfunction (estimated glomerular filtration rate \< 60 ml/min/1.73m2) * patients who didn't write the personal informed consent * any specific therapy for ph.

Keywords: echocardiography lung transplantation
study of adh-1 given intravenously to patients with solid tumors

Conditions: Neoplasms

Summary: n-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. adh-1 blocks n-cadherin. this study will test the safety and effects of adh-1 in subjects with incurable, solid tumors with a protein biomarker called n-cadherin. this study will identify the amount of adh-1 that subjects can tolerate.


Eligibility criteria:
inclusion criteria: * signed written informed consent * male and female patients \> or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists. study currently enrolling only patients with non-small cell lung cancer or advanced ovarian cancer to the safety expansion phase. * clinically or radiologically documented measurable disease. * immunohistochemical evidence of n-cadherin expression (at least 1+ positive) in archived or fresh tumor tissue * adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and electrocardiogram (ecg) exclusion criteria: * receipt of adh-1 prior to this clinical study * chemotherapy, radiotherapy, or any other investigational drug within 30 days before study entry * history of primary brain tumors or brain metastases (known or suspected) unless any lesions have completely resolved following appropriate treatment and there has been no recurrence for at least 6 months. history of spinal cord compression. history of tumors that have shown clinically significant evidence of active bleeding (e.g., gross hemoptysis, hematemesis, hematuria, melena, or bleeding superficial tumor) within 12 weeks before study entry. * stroke, major surgery, or other major tissue injury within 30 days before study entry * history of congestive heart failure, myocardial infarction, angina, life threatening arrhythmias, significant electrocardiogram (ecg) abnormalities, or known hypercoagulable states

Keywords: cancer; tumors; neoplasms; anticarcinogenic agents; antineoplastic agents; cadherins; non-small-cell lung carcinoma; ovarian cancer
interest of saline mr peritoneography for pre-operative assessment of rectal cancer

Conditions: Rectal Adenocarcinoma

Summary: mr saline peritoneography could be useful to demonstrate the peritoneal outline of the pouch of douglas. the investigators think that the localization of the rectal tumor in function of this anatomic mark could be decisive for pre-operative assessment.


Eligibility criteria:
inclusion criteria: * rectal adenocarcinoma exclusion criteria: * metastatic disease * under 18y patient * woman of childbearing age
tracking outcomes in pain patients using fitness devices

Conditions: Chronic Pain; Back Pain

Summary: the investigators are assessing the validity of fitness devices as surrogate measures of chronic pain survey outcomes.

the investigators are attempting to validate the usage of personal fitness trackers against the classical survey tools used. these devices are known to be of use in measuring activity and sleep in healthy patients but their use in chronic pain patients has not been assessed. this study will follow participants with chronic back pain undergoing treatment to see if changes in clinical course can be captured with these fitness devices.

Eligibility criteria:
inclusion criteria: * back pain which may benefit from epidural injection * assenting to epidural injection for back pain exclusion criteria: * inability to wear fitness tracking device

Keywords: fitness devices
photorefractive keratectomy (prk) for hyperopia after radial keratotomy

Conditions: Hyperopia

Summary: to assess the efficacy, predictability, stability and safety of corneal wavefront-guided photorefractive keratectomy (prk) for correcting hyperopia and astigmatism after radial keratotomy (rk).


Eligibility criteria:
inclusion criteria: * hyperopia or hyperopic astigmatism with spherical equivalent of up to + 9,25 d and astigmatism of up to - 4,5 d; * uncorrected visual acuity of 20/40 or worse; * best-corrected visual acuity of 20/60 or better. exclusion criteria: * systemic or ocular conditions that could bias results * previous photorefractive surgery

Keywords: photorefractive keratectomy hyperopia radial keratotomy refractive surgery
study the effects of different doses of uk-369,003 in men with lower urinary tract symptoms.

Conditions: Prostatic Hyperplasia

Summary: this is a 12 week study in which different doses and formulations of uk-369,003 will be administered to patients with a diagnosis of enlarged prostate. patients will complete a series of questionnaires before, during and after treatment to assess if uk-369,003 has improved their urinary symptoms and erectile function . there will be several blood samples taken during the study to asses the level of drug in the blood and correlate it with the responses to the questionnaires.


Eligibility criteria:
inclusion criteria: 1. male subjects aged 40 years and above, with documented luts with an international prostate symptom score (ipss) ≥13 2. clinical diagnosis of bph. 3. qmax 5 to 15ml/sec with a voided volume of ≥150ml at visit 1 (screening). exclusion criteria: 1. urinary tract infection 2. primary neurological conditions affecting bladder function

Keywords: with or without erectile dysfunction
fresh autologous whole blood transfusion after cardiopulmonary bypass

Conditions: Cardiac Disease; Bleeding Postoperative

Summary: autologous blood transfused at the end of cardiopulmonary bypass will reduce total blood loss 24 hours after surgery and improve mitochondrial oxygen delivery measured by plasma succinate levels. the study design is a prospective randomized interventional trial of transfusion of fresh autologous whole blood versus standard of care expectant management of bleeding during elective cardiac surgery.

cardiac surgery carries a significant risk of bleeding requiring transfusion of stored blood products and blood transfusion associated with cardiac surgery consumes 20% of the blood supply worldwide. although transfusion may be life-saving, significant risks of complications such as lung injury or even an increase in mortality are associated with transfusion. decreasing transfusion requirements during cardiac surgery has the potential to reduce the rate of complications, improve patient outcomes, and reduce cost resulting in increased value for both the patient and the health system as a whole. collection of autologous blood before cardiopulmonary bypass (cpb) for transfusion after cpb has been shown to be both safe and effective for reducing blood loss during cardiac surgery, but this intervention has not been targeted to a patient population at high risk for bleeding and transfusion. fresh whole blood has the capacity to restore coagulation system function during profound coagulopathy in a trauma setting or following massive transfusion by an unknown mechanism. one unit of fresh whole blood is able to restore clotting function equivalent to that achieved by 10 units of pooled platelets. autologous whole blood collection prior to cpb for transfusion post-operatively has been shown to improve coagulation and decrease clot lysis but is not routinely performed because 90% to 95% of patients do not have extensive blood loss and subsequent coagulopathy. coupling accurate pre-operative bleeding risk prediction with autologous fresh whole blood collection for transfusion after cpb would target an established, low cost, low risk intervention to an at risk patient population who may experience significant benefit.

Eligibility criteria:
inclusion criteria: 1. adult subjects aged 18 to 90 2. able to provide informed consent 3. willing to accept autologous or allogenic blood transfusion 4. scheduled for elective cardiac surgery with cardiopulmonary bypass exclusion criteria: 1. pre-operative administration of allogenic blood bank products in the previous 3 months 2. hemodynamically unstable defined as a systolic blood pressure less than 90 mmhg with a heart rate greater 100 or requiring intravenous vasopressor medications 3. significant active infection or sepsis defined by positive blood culture or positive wound culture 4. hemoglobin less than 7 g/dl

Keywords: cardiac surgery
nursing care bundle on oral intake among critically ill children with post-extubation dysphagia

Conditions: Oropharyngeal Dysphagia

Summary: the aim of this study is to evaluate the effect of nursing care bundle on oral intake among critically ill children with post-extubation dysphagia

the researchers explained the study's aim, benefits, and procedures for participation, after that the parents of the children provided an informed consent. children's baseline data was collected from their records prior to intervention in order to identify children who meet the required criteria of the study. then the participants were selected and divided randomly (using a simple random method) into two equal groups. one subject for the control group, one for the study group, and so on, distributed the participants into two equivalent groups as fellow: control group: consisted of 30 children who will receive conventional hospital care with no additional interventions. study group: consisted of 30 children who will receive a nursing care bundle on oral intake starting the day after their successful extubation and extend for 14th days. additionally, the participants were provided with a brief education on safe swallowing.

Eligibility criteria:
inclusion criteria: * undergoing emergency oral endotracheal intubation for at least 48 hours * able to communicate and having no sensory deficit and accepted to participate in the research exclusion criteria: * children who had a history of neuromuscular disease, preexisting swallowing problems and agitated children were excluded.
prevalence of antiphospholipid antibodies in the hemodialysis patients population within the chu brugmann hospital

Conditions: Antiphospholipid Syndrome

Summary: in patients with a chronic renal disease at the terminal stage, extrarenal epuration is essential for the control of clinico-biological complications. two extrarenal epuration techniques are currently available: peritoneal dialysis (using the peritoneal membrane of the patient) and hemodialysis, requiring the use of an external biocompatible membrane known as 'dialysis filter'. this technique requires a vascular access (arteriovenous fistula or dialysis catheter). the thrombosis of vascular accesses represents a major cause of morbidity and mortality in hemodialysis patients. thrombosis are more frequent when using synthetic prosthetic arteriovenous fistula instead of native arteriovenous fistula. antiphospholipid syndrome (apls) is a rare autoimmune disease characterized by arterial thrombosis, venous thrombosis and obstetrical complications such as as defined by the sidney's criteria. in the general population, the presence of antiphospholipid antibodies is associated with an increased risk of thromboembolic events. in the nephrological population, this prevalence is higher in hemodialysis patients compared to patients on peritoneal dialysis or non-dialyzed patients. up to 37% of hemodialysis patients are positive for antiphospholipid antibodies and this biology is associated with thrombotic events and vascular access thromboses. however, some studies do not report this association and there is currently no consensus in terms of the therapeutic management of these patients. some factors influencing the positivity for antiphospholipid antibodies have been reported: smoking, age, the presence of a non-glomerular nephropathy, hypoalbuminaemia, the use of a central venous catheter for dialysis or the use of a non-biocompatible dialysis membrane. taking into account the conflicting data from the literature, it seems important to study the respective role(s) of 3 types of antiphospholipid antibodies in the occurrence of thrombo- embolic events in patients undergoing dialysis within the chu brugmann hospital.


Eligibility criteria:
inclusion criteria: - all patients undergoing dialysis within the chu brugmann hospital exclusion criteria: * mutation of factor v * mutation g20210a of the prothrombin gene * protein c deficiency * protein s deficiency * antithrombin iii deficiency
tertiary care with or without manual therapy for chronic migraine

Conditions: Chronic Migraine

Summary: the aim of this study is to determine if adding manual therapy to care as usual reduces the discomfort from chronic migraine compared to care as usual alone


Eligibility criteria:
inclusion criteria: female adults 18 years of age or older with a good command of english (to enable informed consent) existing patients with chronic migraine as diagnosed by a clinical interview with a neurologist in line with the international classification of headache diagnosis criteria (ichd) undergoing care as usual from the neurologist exclusion criteria: currently having or had manual therapy for neck, shoulder in the last six weeks. having a condition contraindicated for manual therapy including but not limited to inflammatory disorders, severe osteoporosis and tumours. identification of any medical 'red flags' by the neurologist including * evidence of any central nervous system involvement for example: * facial palsy (presence of ptosis/horner's syndrome) * visual disturbance (presence of blurred vision, diplopia, hemianopia) * speech disturbance (presence of dysarthria, dysphonia, dysphasia such as expressive or receptive) * balance disturbance (presence of dizziness, imbalance, unsteadiness, falls) * paraesthesia (presence, location such as upper limb/lower limb, face) * weakness (presence, location such as upper limb/lower limb) * known major psychiatric or psychological conditions not under control